Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin

Katherine E. Smith(Mayo Clinic in Arizona), Aaron S. Mansfield(Mayo Clinic), Jennifer Ayers-Ringler(Mayo Clinic), Jeffrey L. Winters(Mayo Clinic), Jacob J. Orme(Mayo Clinic), Fabrice Lucien(Université de Sherbrooke), Yohan Kim(Mayo Clinic)
Scientific Reports
April 16, 2025
10.1038/s41598-025-97952-x
Cited by 2

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Integrating genomic features for non-invasive early lung cancer detection
|Nature|2020|689